BiotechTube

Obexelimab + Obexelimab

Phase 3Active
0 views this week 0 watching💤 Quiet
Interest: 38/100
38
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Warm Autoimmune Hemolytic Anemia

Conditions

Warm Autoimmune Hemolytic Anemia

Trial Timeline

Sep 25, 2023 → Aug 31, 2026

NCT ID
NCT05786573

About Obexelimab + Obexelimab

Obexelimab + Obexelimab is a phase 3 stage product being developed by Zenas BioPharma for Warm Autoimmune Hemolytic Anemia. The current trial status is active. This product is registered under clinical trial identifier NCT05786573. Target conditions include Warm Autoimmune Hemolytic Anemia.

What happened to similar drugs?

0 of 5 similar drugs in Warm Autoimmune Hemolytic Anemia were approved

Approved (0) Terminated (1) Active (4)
🔄Ianalumab + PlaceboNovartisPhase 3
🔄rituximab (Mabthera®) + PlaceboRochePhase 3
❌parsaclisinib + placeboIncytePhase 3
🔄Fostamatinib disodiumRigel PharmaceuticalsPhase 3
🔄Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical
17
Activity
12
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05786573Phase 3Active

Competing Products

12 competing products in Warm Autoimmune Hemolytic Anemia

See all competitors
ProductCompanyStageHype Score
Ianalumab + PlaceboNovartisPhase 3
44
rituximab (Mabthera®) + PlaceboRochePhase 3
40
rilzabrutinibSanofiPhase 2
39
Isatuximab SAR650984SanofiPhase 2
27
parsaclisinib + placeboIncytePhase 3
29
RVT-1401 680 mg/weekly + RVT-1401 340 mg/weeklyImmunovantPhase 2
24
HMPL-523(300mg PO QD) + PlaceboHUTCHMEDPhase 2/3
36
APL-2Apellis PharmaceuticalsPhase 2
29
ANX005AnnexonPhase 2
29
Fostamatinib 150 mg bidRigel PharmaceuticalsPhase 2
29
Fostamatinib disodiumRigel PharmaceuticalsPhase 3
41
Fostamatinib disodium + PlaceboRigel PharmaceuticalsPhase 3
34